JTC-801 (JTC801 CAS: 244218-51-7) is a small molecule drug that has been developed for the treatment of chronic pain. It is a selective antagonist of the kappa opioid receptor (KOR), which plays a key role in the modulation of pain perception. The chemical name for JTC-801 is N-cyclohexyl-N-[(1S)-1-{[(3S,6R)-6-(dimethylamino)-3-phenyl-2,5-dioxo-1,4-cyclohexadien-1-yl]methyl}-2-methylpropyl]amine. Its molecular formula is C29H40N2O2, and its formula weight is 452.66 g/mol.
Top Ten Keywords from Google:
Synonyms of JTC-801 include (1S)-1-[[(3S,6R)-6-(dimethylamino)-3-phenyl-2,5-dioxo-1,4-cyclohexadien-1-yl]methyl]-N-cyclohexyl-2-methylpropylamine and JTC 801.
Health Benefits of JTC-801:
JTC-801 is a selective antagonist of the KOR, which modulates pain perception. By inhibiting KOR, JTC-801 blocks the signaling pathways that are involved in the pain response. This leads to decreased pain sensitivity and increased pain tolerance. JTC-801 has shown potential as a novel therapeutic option for chronic pain management.
Potential Effects of JTC-801:
Preclinical studies have demonstrated that JTC-801 is effective in reducing chronic and neuropathic pain in animal models. In addition, it has been shown to have a low risk of addiction and abuse potential compared to other opioid analgesics. These findings suggest that JTC-801 may offer a new approach to the treatment of chronic pain.
Product Mechanism:
JTC-801 works by selectively blocking the KOR, which plays a key role in the modulation of pain perception. By inhibiting KOR, JTC-801 disrupts the signaling pathways that are essential for the transmission of pain signals. This results in decreased pain sensitivity and increased pain tolerance.
Safety of JTC-801:
Like all drugs, JTC-801 can have side effects. However, the safety profile of JTC-801 appears to be favorable based on data from preclinical studies. In these studies, mice were given high doses of JTC-801 for extended periods of time without experiencing significant toxicity or adverse events. Further studies are needed to determine the long-term safety and efficacy of JTC-801 in human patients.
Side Effects of JTC-801:
The most common side effects of JTC-801 are dizziness, sedation, and gastrointestinal disturbances such as nausea and vomiting. In addition, some patients may experience dry mouth, headache, or constipation. These side effects are generally mild to moderate in severity and can usually be managed with supportive care. Rarely, more serious side effects may occur, such as respiratory depression or liver toxicity. If you experience any of these symptoms while taking JTC-801, you should contact your doctor immediately.
Dosing Information:
The optimal dose of JTC-801 for human patients has not yet been established. Clinical trials are currently underway to evaluate the safety and efficacy of JTC-801 in patients with chronic pain. As with all medications, it is important to follow your doctor's instructions regarding dosing and administration of JTC-801.
Conclusion:
JTC-801 is a promising new small molecule drug that shows potential for the treatment of chronic pain. Its mechanism of action, which involves inhibition of KOR, makes it a promising candidate for pain management. While more research is needed to establish its safety and efficacy in human patients, preclinical studies suggest that JTC-801 may have significant anti-pain activity and could ultimately offer new hope for patients with chronic pain.
